
Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity
Keywords: SCT, stem cell transplantation; CTLA-4, cytotoxic T lymphocyte-associated antigen-4; GVHD, graft-vs.-host disease; GVM, graft-vs.-malignancy; GVL, graft-vs.-leukemia effects; DLI, donor lymphocyte infusion; MRD, minimal residual disease; irAEs, immune-rel